Lineage Cell Therapeutics Inc (LCTX) — Capital Reinvestment Ratio
Lineage Cell Therapeutics Inc (LCTX) has a Capital Reinvestment Ratio of 0.00x as of March 2022, meaning it reinvests 0% of its operating cash flow ($21.90 Million) in capital expenditures ($46.00K). See net asset quality index of Lineage Cell Therapeutics Inc to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Lineage Cell Therapeutics Inc Capital Reinvestment Ratio (2022–2022)
This chart tracks Lineage Cell Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods. Check total reinvestment intensity of Lineage Cell Therapeutics Inc to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Lineage Cell Therapeutics Inc (2022–2022)
Year-by-year Capital Reinvestment Ratio for Lineage Cell Therapeutics Inc from 2022 to 2022. For live market cap and broader valuation context, see Lineage Cell Therapeutics Inc market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.39x | $1.06 Million | $413.00K | — |